# Mimedx Group, Inc.: overview

MDXG · Nasdaq · CIK 1376339 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mdxg.md) · [Financials](/companies/mdxg/financials.md) · [Filings](/companies/mdxg/filings.md) · [Insiders](/companies/mdxg/insiders.md)

Latest reported revenue: [$64.4m](/filings/0001376339-26-000071.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001376339-26-000071).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [84.1](/filings/0001376339-25-000103.md) | [92.9 d](/filings/0001376339-26-000011.md) | [88.2](/filings/0001376339-26-000031.md) | [98.6](/filings/0001376339-26-000071.md) | [114](/filings/0001376339-25-000103.md) | [118 d](/filings/0001376339-26-000011.md) | [59.0](/filings/0001376339-26-000031.md) | [64.4](/filings/0001376339-26-000071.md) |
| Gross margin | % | [81.8%](/filings/0001376339-25-000103.md) | [81.8% d](/filings/0001376339-26-000011.md) | [81.2%](/filings/0001376339-26-000031.md) | [81.1%](/filings/0001376339-26-000071.md) | [83.5%](/filings/0001376339-25-000103.md) | [83.9% d](/filings/0001376339-26-000011.md) | [70.6%](/filings/0001376339-26-000031.md) | [69.0%](/filings/0001376339-26-000071.md) |
| Operating margin | % | [13.3%](/filings/0001376339-25-000103.md) | [11.9% d](/filings/0001376339-26-000011.md) | [9.4%](/filings/0001376339-26-000031.md) | [12.5%](/filings/0001376339-26-000071.md) | [19.5%](/filings/0001376339-25-000103.md) | [17.8% d](/filings/0001376339-26-000011.md) | [(27.2%)](/filings/0001376339-26-000031.md) | [(28.7%)](/filings/0001376339-26-000071.md) |
| Net margin | % | [9.6%](/filings/0001376339-25-000103.md) | [8.0% d](/filings/0001376339-26-000011.md) | [8.0%](/filings/0001376339-26-000031.md) | [9.8%](/filings/0001376339-26-000071.md) | [14.7%](/filings/0001376339-25-000103.md) | [12.9% d](/filings/0001376339-26-000011.md) | [(18.4%)](/filings/0001376339-26-000031.md) | [(23.1%)](/filings/0001376339-26-000071.md) |
| Diluted EPS | $ per share | [0.05](/filings/0001376339-25-000103.md) | not reported | [0.05](/filings/0001376339-26-000031.md) | [0.06](/filings/0001376339-26-000071.md) | [0.11](/filings/0001376339-25-000103.md) | not reported | [(0.07)](/filings/0001376339-26-000031.md) | [(0.10)](/filings/0001376339-26-000071.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [242](/filings/0001376339-24-000009.md) | [268](/filings/0001376339-25-000009.md) | [321](/filings/0001376339-26-000011.md) | [349](/filings/0001376339-26-000011.md) | [419](/filings/0001376339-26-000011.md) |
| Gross margin | % | [83.6%](/filings/0001376339-24-000009.md) | [82.0%](/filings/0001376339-25-000009.md) | [83.0%](/filings/0001376339-26-000011.md) | [82.8%](/filings/0001376339-26-000011.md) | [82.6%](/filings/0001376339-26-000011.md) |
| Operating margin | % | [(2.9%)](/filings/0001376339-24-000009.md) | [(5.5%)](/filings/0001376339-25-000009.md) | [11.5%](/filings/0001376339-26-000011.md) | [16.9%](/filings/0001376339-26-000011.md) | [15.3%](/filings/0001376339-26-000011.md) |
| Net margin | % | [(4.2%)](/filings/0001376339-24-000009.md) | [(11.3%)](/filings/0001376339-25-000009.md) | [18.1%](/filings/0001376339-26-000011.md) | [12.2%](/filings/0001376339-26-000011.md) | [11.6%](/filings/0001376339-26-000011.md) |
| Diluted EPS | $ per share | [(0.15)](/filings/0001376339-24-000009.md) | [(0.33)](/filings/0001376339-25-000009.md) | [0.37](/filings/0001376339-26-000011.md) | [0.28](/filings/0001376339-26-000011.md) | [0.32](/filings/0001376339-26-000011.md) |
| Free cash flow | $m | [(5.2)](/filings/0001376339-24-000009.md) | [(19.4)](/filings/0001376339-25-000009.md) | [24.8](/filings/0001376339-26-000011.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mdxg/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Essex Woodlands Management, Inc.](/funds/1542339.md) | 2026-06-30 | $108.6m | 28,195,249 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $46.8m | 12,154,466 |  | Added +243,166 |
| [Trigran Investments, Inc.](/funds/1336800.md) | 2026-06-30 | $27.6m | 7,173,770 |  | Reduced −1,339 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $21.5m | 5,578,920 |  | Added +522,119 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $20.0m | 5,187,053 |  | Added +21,047 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $18.4m | 4,767,552 |  | Added +1,370,253 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $18.4m | 4,767,552 |  | Added +1,370,253 |
| [PARADIGM CAPITAL MANAGEMENT INC/NY](/funds/1037792.md) | 2026-06-30 | $15.7m | 4,073,100 |  | Added +662,800 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $12.1m | 3,143,488 |  | Added +262,329 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $10.3m | 2,665,562 |  | Added +1,480,001 |

## Recent filings

[All 1,205 filings](/companies/mdxg/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-16 | 13:01 ET | [8-K](/filings/0001213900-26-110041.md) | 8.01 Other events | 0001213900-26-110041 |
| 2026-08-11 | 20:44 ET | [8-K/A](/filings/0001376339-26-000082.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001376339-26-000082 |
| 2026-07-29 | 20:08 ET | [8-K](/filings/0001376339-26-000074.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001376339-26-000074 |
| 2026-07-29 | 20:06 ET | [10-Q](/filings/0001376339-26-000071.md) | Quarterly report, period 2026-06-30 | 0001376339-26-000071 |
| 2026-07-29 | 20:03 ET | [8-K](/filings/0001376339-26-000070.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001376339-26-000070 |
| 2026-06-16 | 20:12 ET | [8-K](/filings/0001376339-26-000052.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results | 0001376339-26-000052 |
| 2026-04-29 | 20:02 ET | [DEF 14A](/filings/0001376339-26-000033.md) | Proxy statement, period 2025-12-31 | 0001376339-26-000033 |
| 2026-04-29 | 20:01 ET | [8-K](/filings/0001376339-26-000032.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001376339-26-000032 |
| 2026-04-29 | 20:00 ET | [10-Q](/filings/0001376339-26-000031.md) | Quarterly report, period 2026-03-31 | 0001376339-26-000031 |
| 2026-04-16 | 12:04 ET | [8-K](/filings/0001376339-26-000021.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001376339-26-000021 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001376339-26-000011.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/df69ea46-4036-4cf6-a8e6-2241a8488025)

## About the filer

- CIK: 1376339
- Tickers: MDXG
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.